Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Vantage Biosciences logo — Transforming diabetic eye disease with an oral treatment

Vantage Biosciences

Transforming diabetic eye disease with an oral treatment

Founded 2023 United Kingdom London, United Kingdom 6 employees Seed Biotechnology, Health Care +1

General Information

Company Name Vantage Biosciences
Founded Year 2023
Location United Kingdom London, United Kingdom
Employees 6
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Seed
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Vantage Biosciences. To contact Vantage Biosciences, visit vantage-biosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vantage Biosciences compare?

A PDF of Vantage Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vantage Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vantage Biosciences

Vantage Biosciences, founded in 2023, is a promising clinical stage biotechnology company based in the United Kingdom. Specializing in addressing the root causes of diabetic eye disease, Vantage focuses on the neuroinflammatory processes that trigger microangiopathy and the subsequent degeneration of the neurovascular unit in the eye.

By working toward an innovative oral treatment solution, Vantage aims to transform how diabetic eye disease is managed, offering a proactive, disease-modifying approach that intervenes early in disease progression. Their slogan, "Transforming diabetic eye disease with an oral treatment," encapsulates this mission.

Operating primarily in the Biotechnology and Health Care sectors, the company received its last investment as a Seed investment on 01 January 2023 from ALSA Ventures. This support underscores investor confidence in Vantage's innovative approach and potential impact on health and wellness.

Business keywords: Clinical Stage, Neuroinflammatory Disease, Vision Loss Prevention, Diabetic Eye Disease, Ophthalmology, Pharmaceutical Development, Disease Modifying Therapy, Neurovascular Disorders, Drug Development, Diabetes-related Complications, Eye Health, Therapeutic Innovation, Microangiopathy

Services & Products

Drug development for inflammatory conditions
Oral treatments creation for diabetic retinopathy
Clinical trials execution

Target Customers

Patients with inflammatory diseases Individuals with diabetic eye disease Healthcare providers and clinics

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Undisclosed 1
ALSA Ventures
ALSA Ventures
01 Jan 2023

Vantage Biosciences Alternatives & Competitors

View All Alternatives
Vantage Biosciences vs
FimmCyte
FimmCyte Switzerland

First disease modifying treatment for Endometriosis.

Seed
7 employees
Biotechnology, Health Care
Vantage Biosciences vs
Novaliq GmbH
Novaliq GmbH Germany

Transforming Ocular Therapeutics

Series F+
23 employees
Biotechnology, Health Care
Vantage Biosciences vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Vantage Biosciences

Transforming diabetic eye disease with an oral treatment
Vantage Biosciences was founded in 2023.
Vantage Biosciences is headquartered in London, United Kingdom.
Vantage Biosciences operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Clinical Stage, Neuroinflammatory Disease, Vision Loss Prevention and Diabetic Eye Disease. Its customers include Patients with inflammatory diseases, Individuals with diabetic eye disease and Healthcare providers and clinics.
Vantage Biosciences has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Vantage Biosciences has approximately 6 employees.
Vantage Biosciences has completed 1 funding round. The latest funding stage is Seed.
Vantage Biosciences offers: Drug development for inflammatory conditions, Oral treatments creation for diabetic retinopathy, Clinical trials execution.
Top alternatives and competitors to Vantage Biosciences include FimmCyte, Novaliq GmbH, Tridek-One, AAVantgarde, BIORCHESTRA Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vantage Biosciences and FimmCyte are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vantage Biosciences, https://bouncewatch.com/company/vantage-biosciences, updated 15 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes